|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM373400527 |
| 003 |
DE-627 |
| 005 |
20250306070608.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240609s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202401495
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1243.xml
|
| 035 |
|
|
|a (DE-627)NLM373400527
|
| 035 |
|
|
|a (NLM)38851884
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhen, Xueyan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Biointerface-Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.10.2024
|
| 500 |
|
|
|a Date Revised 10.10.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a The tumor microenvironment (TME) of typical tumor types such as triple-negative breast cancer is featured by hypoxia and immunosuppression with abundant tumor-associated macrophages (TAMs), which also emerge as potential therapeutic targets for antitumor therapy. M1-like macrophage-derived exosomes (M1-Exos) have emerged as a promising tumor therapeutic candidate for their tumor-targeting and macrophage-polarization capabilities. However, the limited drug-loading efficiency and stability of M1-Exos have hindered their effectiveness in antitumor applications. Here, a hybrid nanovesicle is developed by integrating M1-Exos with AS1411 aptamer-conjugated liposomes (AApt-Lips), termed M1E/AALs. The obtained M1E/AALs are loaded with perfluorotributylamine (PFTBA) and IR780, as P-I, to construct P-IM1E/AALs for reprogramming TME by alleviating tumor hypoxia and engineering TAMs. P-I@M1E/AAL-mediated tumor therapy enhances the in situ generation of reactive oxygen species, repolarizes TAMs toward an antitumor phenotype, and promotes the infiltration of T lymphocytes. The synergistic antitumor therapy based on P-I@M1E/AALs significantly suppresses tumor growth and prolongs the survival of 4T1-tumor-bearing mice. By integrating multiple treatment modalities, P-I@M1E/AAL nanoplatform demonstrates a promising therapeutic approach for overcoming hypoxic and immunosuppressive TME by targeted TAM reprogramming and enhanced tumor photodynamic immunotherapy. This study highlights an innovative TAM-engineering hybrid nanovesicle platform for the treatment of tumors characterized by hypoxic and immunosuppressive TME
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a M1‐like macrophage
|
| 650 |
|
4 |
|a antitumor therapy
|
| 650 |
|
4 |
|a exosome
|
| 650 |
|
4 |
|a hypoxia alleviation
|
| 650 |
|
4 |
|a tumor microenvironment reprogramming
|
| 650 |
|
4 |
|a tumor‐associated macrophage
|
| 650 |
|
7 |
|a Liposomes
|2 NLM
|
| 650 |
|
7 |
|a Aptamers, Nucleotide
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Reactive Oxygen Species
|2 NLM
|
| 700 |
1 |
|
|a Li, Yongjiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Wanqing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Tingting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Min
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Jinhai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kong, Na
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xie, Xiaoyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Sicen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tao, Wei
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 41 vom: 01. Okt., Seite e2401495
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:41
|g day:01
|g month:10
|g pages:e2401495
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202401495
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 41
|b 01
|c 10
|h e2401495
|